GLP-1 receptor agonists
Browse the latest news, expert commentary, and educational content on the GLP-1 receptor agonist medication class.
The STEP and SELECT trials
Keep up with the news and expert comment on the STEP and SURMOUNT phase 3 trials of semaglutide 2.4 mg in people with obesity.
The SURPASS trials
Click through for clinical trial updates and expert reaction to the SURPASS and SURMOUNT phase 3 trials of the novel dual-action medication tirzepatide in people with type 2 diabetes and/or obesity.
Beyond glucose lowering | Cardioprotection
07-02-2019 | Dulaglutide | Podcast | Article
REWIND, DECLARE, and high-risk diabetes patients
How will the findings of the REWIND trial and the DECLARE-TIMI 58 renal outcomes analysis affect treatment decisions for high-risk diabetes patients without overt cardiovascular disease? medwireNews asks Kamlesh Khunti.
Beyond glucose lowering | Novel formulations
The clinical trials
10-14-2020 | Tirzepatide | At a glance | Article
A quick guide to the SURPASS and SURMOUNT trials
Phase 3 trials of tirzepatide in type 2 diabetes and obesity
Read our overview of the SURPASS trials of the dual GLP-1/GIP receptor agonist tirzepatide in people with type 2 diabetes, plus the SURMOUNT trials in people with obesity.
02-11-2021 | Semaglutide | At a glance | Article
A quick guide to the STEP trials
Read our round-up of the STEP phase 3 trials of semaglutide 2.4 mg in people with obesity, plus the SELECT cardiovascular outcomes trial.
Stay informed with Medicine Matters
Get the latest developments in diabetes delivered straight to your inbox